Impact of Product-Related Factors on Immunogenicity of Biotherapeutics

Singh, Satish Kumar·2011·Journal of Pharmaceutical Sciences
DOI 10.1002/jps.22276

Cited by (350)

Items 301–350 of 350

  1. Therapeutic antibody development—Remington chapter
    Brian J. Geist, Songmao Zheng, Yan Xu · 2020 · Elsevier eBooks
  2. Specificity of treatment response to infliximab in patients with inflammatory bowel disease and ankylosing spondylitis
    T. YU. NURIAKHMETOVA, Ildaria K. Valeeva, Ya. O. Shevnina, Petrov Av, Alfiya Kh. Odintsova, Абдракипов Рифкат Завдятович, Timur B. Sibgatullin, A.G. Vasil’ev, Diana Ildarovna Abdulganieva · 2021 · Russian Medical Inquiry
  3. CLINICAL PHARMACOLOGY, TOXICOLOGY, AND THERAPEUTIC DOSAGE AND RESPONSE
    Rodney J. Y. Ho, Milo Gibaldi · 2013
  4. The Immunogenicity Database Collaborative (IDC): A Standardized, Publicly Available Database for Clinical Immunogenicity Observations and Insights
    Sudhanshu Agnihotri, Bruno Gonzalez-Nolasco, Brinda Monian, Sofie Pattijn, Chloé Ackaert, Patrick Wu, Hubert Kettenberger, Sophie Tourdot, Timothy Paul Hickling, Zicheng Hu et al. · 2025 · bioRxiv (Cold Spring Harbor Laboratory)
  5. Clinical Manifestations of an Anti-Drug Antibody Response: Autoimmune Reactions
    Steven J. Swanson · 2014 · Journal of Interferon & Cytokine Research
  6. Bioanalytical Methods and Immunogenicity Assays
    Bonita J. Rup, Corinna Krinos‐Fiorotti, Boris Gorovits, Hendrik Neubert · 2014
  7. Immunogenicity of Protein Therapeutics: Risk Assessment and Risk Mitigation
    Harald Kropshofer · 2014 · Methods and principles in medicinal chemistry
  8. Nonclinical Safety Assessment of Biotechnology‐Derived Products: Considerations and Challenges
    Barbara J. Mounho · 2014
  9. Techniques to Improve the Characterization of Protein Particles in Biologic Drug Products
    Maria R. Toler · 2012 · KU ScholarWorks (University of Kansas)
  10. Adverse side-effects of biological agents: Hypersensitivity reactions
    Zorica Stojić-Vukanić, Nevena Arsenović-Ranin, Jelena Antić‐Stanković, Marina Milenković · 2014 · Arhiv za farmaciju
  11. Molecular approaches to chemotherapeutic targeting
    Krista Wager · 2012
  12. Го лимумаб в лечении воспалительных заболеваний: роль иммуногенности
    Dmitry Evgenyevich Karateev, В А Насонова · 2015
  13. Immunogenicity of Therapeutic Proteins: Antibody Responses in Mice to Particulates Formed by Adsorbing a Murine Monoclonal Antibody onto Microparticles
    Maliheh Shomali · 2013 · CU Scholar (University of Colorado Boulder)
  14. The role of toll-like receptors in assisted conception
    Wedad Aboussahoud · 2016 · Research Explorer (The University of Manchester)
  15. TRENDS IN FORMULATION AND DRUG DELIVERY FOR ANTIBODIES
    Hanns‐Christian Mahler, Roman Mathäs · 2017 · Wiley eBooks
  16. Retracted: Molecular characterization of excipients’ preferential interactions with therapeutic monoclonal antibodies
    Jehoon Kim, Mark R.H. Krebs, Bernhardt L. Trout · 2017 · Journal of Pharmacy and Pharmacology · Retracted
  17. Development of an immunoassay to detect tobacco host cell proteins during biopharmaceutical development
    Zulfaquar Ahmad Arfi, Rainer Fischer, Stefan Schillberg · 2015 · RWTH Publications (RWTH Aachen)
  18. Characterizing Novel Modifications of a Therapeutic Protein Using Ultra Performance Liquid Chromatography–Tandem Mass Spectrometry, Sedimentation Velocity Analytical Ultracentrifugation, and Structural Modeling
    Yu Shi, Xuan Hong, Haihong Fan, Zhuchun Wu, Aston Liu · 2018 · Analytical Chemistry
  19. Drug Product Considerations for Biosimilars
    Satish Kumar Singh, Susanne Joerg, Hanns‐Christian Mahler · 2018 · AAPS advances in the pharmaceutical sciences series
  20. UNDERSTANDING PHYSIOLOGY OF DISEASES AND CELL LINES USING OMICS BASED APPROACHES
    Amit Kumar · 2015
  21. Investigating the immunogenicity of therapeutic proteins : protein aggregation and host cell protein impurities
    Kirsty D. Ratanji · 2017 · Research Explorer (The University of Manchester)
  22. Integrating upstream and downstream process development strategies for mammalian cell derived therapeutic antibodies
    Louisa J. Wilson · 2020 · UCL Discovery (University College London)
  23. - Methods for the Analysis of Plasma and Plasma Protein Fractions
    Roger L. Lundblad · 2012 · CRC Press eBooks
  24. Dynamics of unfolded protein aggregation
    Upadhyay, Utkarsh, Chandrima Barua, Devi, Shivani, Jay Prakash Kumar, R. K. Brojen Singh · 2021 · arXiv (Cornell University)
  25. Faculty Opinions recommendation of Regulatory and strategic considerations for addressing immunogenicity and related responses in biopharmaceutical development programs.
    Mark E. Cartwright · 2021 · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature
  26. Immunogenicity considerations
    2015 · CRC Press eBooks
  27. Methods for the Analysis of Plasma and Plasma Protein Fractions
    2012 · Protein science series
  28. Drug Safety
    2013 · Drug Safety
  29. Immunogenicity of Botulinum Toxin Formulations: Potential Therapeutic Implications
    Warner W. Carr, Neal Jain, James Wesley Sublett · 2022 · Toxicon
  30. Pharmaceutical aspects of mAbs: formulation, characterization, and current route of administration of monoclonal antibody therapies
    Amal Elkordy, Cheng Shu Chaw · 2023 · Elsevier eBooks
  31. Additional file 1 of Title: insoluble proteins catch heterologous soluble proteins into inclusion bodies by intermolecular interaction of aggregating peptides
    José Vicente Carratalá, Andrés Cisneros, Elijah Hellman, Antonio Villaverde, Neus Ferrer‐Miralles · 2021 · Figshare
  32. Additional file 5 of Title: insoluble proteins catch heterologous soluble proteins into inclusion bodies by intermolecular interaction of aggregating peptides
    José Vicente Carratalá, Andrés Cisneros, Elijah Hellman, Antonio Villaverde, Neus Ferrer‐Miralles · 2021 · Figshare
  33. Additional file 1 of Modeling the behavior of monoclonal antibodies on hydrophobic interaction chromatography resins
    Douglas Nolan, Thomas R. Chin, Mick Eamsureya, Sheldon Oppenheim, Olga Paley, Christina Alves, George Parks · 2024 · Figshare
  34. Additional file 4 of Title: insoluble proteins catch heterologous soluble proteins into inclusion bodies by intermolecular interaction of aggregating peptides
    José Vicente Carratalá, Andrés Cisneros, Elijah Hellman, Antonio Villaverde, Neus Ferrer‐Miralles · 2021 · Figshare
  35. Additional file 2 of Title: insoluble proteins catch heterologous soluble proteins into inclusion bodies by intermolecular interaction of aggregating peptides
    José Vicente Carratalá, Andrés Cisneros, Elijah Hellman, Antonio Villaverde, Neus Ferrer‐Miralles · 2021 · Figshare
  36. Additional file 2 of Modeling the behavior of monoclonal antibodies on hydrophobic interaction chromatography resins
    Douglas Nolan, Thomas R. Chin, Mick Eamsureya, Sheldon Oppenheim, Olga Paley, Christina Alves, George Parks · 2024 · Figshare
  37. Additional file 3 of Modeling the behavior of monoclonal antibodies on hydrophobic interaction chromatography resins
    Douglas Nolan, Thomas R. Chin, Mick Eamsureya, Sheldon Oppenheim, Olga Paley, Christina Alves, George Parks · 2024 · Figshare
  38. Additional file 3 of Title: insoluble proteins catch heterologous soluble proteins into inclusion bodies by intermolecular interaction of aggregating peptides
    José Vicente Carratalá, Andrés Cisneros, Elijah Hellman, Antonio Villaverde, Neus Ferrer‐Miralles · 2021 · Figshare
  39. Cytokine expression mediated immunogenic response of therapeutic IgG aggregates obtained by forced degradative stress factors and the role of a deep neural network in its prediction
    Rozaleen Dash, Shravan Sreenivasan, Anandi Chowdhury, Naveen G. Jesubalan, Narendra B. Chirmule, Zuben E. Sauna, Anurag S. Rathore · 2026 · Biochemical and Biophysical Research Communications
  40. Conception et production d’anticorps anti-TNFa non immunogènes pour le traitement des maladies inflammatoires
    Coline Sivelle · 2019
  41. Approches analytiques pour l'analyse et la caractérisation d'anticorps thérapeutiques dégradés : intérêt de la spectrométrie de masse en mode non-dénaturant
    Minh Thang Le · 2019
  42. Agrégation et immunisation contre les protéines thérapeutiques : étude de la maturation des cellules dendritiques et de la réponse lymphocytaire
    Myriam Nabhan · 2019 · theses.fr (ABES)
  43. Développement analytique combiné à l'approche prédictive ASAP pour l'étude de la stabilité de produits pharmaceutiques chimiques et biologiques
    Pauline Legrand · 2022
  44. Mechanism-informed evaluation of particle formation in high-concentration monoclonal antibodies during fill–finish: Impact of pump materials, surface interactions, and system architecture
    Adam Hartman, Deep S. Bhattacharya, Mingyue Li, Vicky Lin, Eda Fenercioglu, Patrice Anleitner, Advait V. Badkar, Parag Kolhe · 2026 · Journal of Pharmaceutical Sciences
  45. Migraine, monoclonal antibodies, and monitoring: a review of pharmacovigilance in the era of biologics
    Lorenza Guarnieri, Francesca Bosco, Maria Tiziana Corasaniti, Rita Citraro, Giovambattista De Sarro · 2026 · Frontiers in Pharmacology
  46. The immunogenicity database collaborative: a standardized, publicly available database for clinical immunogenicity observations and insights
    Sudhanshu Agnihotri, Bruno Gonzalez-Nolasco, Brinda Monian, Sofie Pattijn, Chloé Ackaert, Patrick Wu, Hubert Kettenberger, Sophie Tourdot, Timothy Paul Hickling, Zicheng Hu et al. · 2026 · Frontiers in Immunology
  47. From analytical similarity to clinical confidence: how regulatory evolution ensures comparable immunogenicity in streamlined biosimilar development
    Sandra Ribes, Marc Rosenbaum, Laura Hartmann, Lisa Allmannsberger, Johann Poetzl · 2026 · Bioanalysis
  48. Immunogenicity of biologics delivered in the subcutaneous space: Delineating the contributing factors
    Vibha Jawa, Sophie Tourdot, Manjunath Shivaraju, Marisa Joubert, Sathy V. Balu‐Iyer, Kari Cox, Ming Cheng, Ying Chen, Masano Huang, Karoline Bechtold Peters et al. · 2026 · Journal of Pharmaceutical Sciences
  49. In silico and in vitro immunogenicity risk assessment of process- and product-related protein impurities reported in adenoviral-vectored COVID-19 vaccines
    Anne Searls De Groot, Benjamin Gabriel, Mitchell McAllister, Tamako Garcia, Vibha Jawa · 2026 · Journal of Pharmaceutical Sciences
  50. Development of immunogenicity models in mice for improved risk assessment of biopharmaceuticals
    Britta Granath · 2013 · Gothenburg University Publications Electronic Archive (Gothenburg University)